Free Trial

C4 Therapeutics (CCCC) News Today

C4 Therapeutics logo
$2.18 -0.04 (-1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$2.16 -0.02 (-0.69%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
C4 Therapeutics, Inc. stock logo
Equities Analysts Offer Predictions for C4 Therapeutics Q2 Earnings
C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Research analysts at Brookline Capital Management issued their Q2 2025 earnings estimates for C4 Therapeutics in a note issued to investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann expects that the company will po
Stifel Nicolaus Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)
C4 Therapeutics, Inc. stock logo
C4 Therapeutics (NASDAQ:CCCC) Releases Earnings Results, Misses Expectations By $0.05 EPS
C4 Therapeutics (NASDAQ:CCCC - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%.
C4 Therapeutics, Inc. stock logo
C4 Therapeutics (NASDAQ:CCCC) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
C4 Therapeutics (NASDAQ:CCCC - Get Free Report) issued its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%.
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Decrease in Short Interest
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,400,000 shares, a decrease of 20.3% from the January 15th total of 9,280,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the short-interest ratio is presently 4.4 days.
C4 Therapeutics, Inc. stock logo
C4 Therapeutics (CCCC) to Release Quarterly Earnings on Thursday
C4 Therapeutics (NASDAQ:CCCC) will be releasing earnings on Thursday, February 20, Financial Modeling Prep reports.
C4 Therapeutics announces anticipated 2025 milestones
C4 Therapeutics price target raised to $50 from $39 at Brookline
C4 Therapeutics, Inc. stock logo
Equities Analysts Issue Forecasts for C4 Therapeutics FY2029 Earnings
C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Brookline Capital Management issued their FY2029 earnings estimates for shares of C4 Therapeutics in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn $28.08 per share for t
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 11.0% in December
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 8,870,000 shares, an increase of 11.0% from the November 30th total of 7,990,000 shares. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 7.3 days.
C4 Therapeutics, Inc. stock logo
State Street Corp Cuts Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)
State Street Corp lowered its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 6.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,806,913 shares of the company's stock afte
Wells Fargo Upgrades C4 Therapeutics (CCCC)
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the co
C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
C4 Therapeutics, Inc. stock logo
C4 Therapeutics (NASDAQ:CCCC) Upgraded to "Overweight" at Wells Fargo & Company
Wells Fargo & Company upgraded shares of C4 Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $8.00 to $12.00 in a research report on Thursday.
C4 Therapeutics, Inc. stock logo
Fmr LLC Raises Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)
Fmr LLC increased its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 687.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,941 shares of the company's stock after acquirin
C4 Therapeutics
C4 Therapeutics (CCCC) Gets a Hold from Morgan Stanley
C4 Therapeutics, Inc. stock logo
Point72 Asset Management L.P. Boosts Stock Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)
Point72 Asset Management L.P. grew its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 331.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,201,848 shares of the company's stock after buying an additio
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Bought by Wasatch Advisors LP
Wasatch Advisors LP grew its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 17.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,677,368 shares of the company's stock after purchasing an additional 830,218 shares dur
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Hold" from Analysts
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has been given an average recommendation of "Hold" by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recomme
C4 Therapeutics appoints Hoerter to board of directors
C4 Therapeutics Appoints Steve Hoerter to Board
C4 Therapeutics initiated with an Equal Weight at Stephens
C4 Therapeutics, Inc. stock logo
C4 Therapeutics (NASDAQ:CCCC) Now Covered by Analysts at Stephens
Stephens assumed coverage on shares of C4 Therapeutics in a research note on Monday. They set an "equal weight" rating and a $4.00 price objective for the company.
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 5,850,000 shares, a decrease of 12.0% from the October 15th total of 6,650,000 shares. Based on an average trading volume of 975,000 shares, the days-to-cover ratio is currently 6.0 days.
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Stifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC)
Morgan Stanley Keeps Their Hold Rating on C4 Therapeutics (CCCC)
C4 Therapeutics Advances in Protein Degradation Therapy
C4 Therapeutics files $400M mixed securities shelf
C4 Therapeutics files to sell 4.87M shares of common stock for holders
C4 Therapeutics, Inc. stock logo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by Brokerages
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a bu
Remove Ads
Get C4 Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.

CCCC Media Mentions By Week

CCCC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CCCC
News Sentiment

0.00

0.68

Average
Medical
News Sentiment

CCCC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CCCC Articles
This Week

0

2

CCCC Articles
Average Week

Remove Ads
Get C4 Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CCCC) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners